Materials and methods

Chemicals
TCEP·HCl and K 2 CO 3 were purchased from Sigma-Aldrich, CH 2 . All reagents were used as received without further purification. 13 C nuclear magnetic resonance spectra were acquired on Bruker AVIII-400 (400 MHz), Bruker AV-500 (500 MHz), Bruker AVIII HD-600 (600 MHz) and Bruker AVII-800 (800 MHz) spectrometers, using D 2 O or CDCl 3 (or other deuterated solvent as specified)
1 H and proton-decoupled
as a reference for the internal deuterium lock. Chemical shifts (δ) for each signal are quoted in parts per million (ppm) relative to tetramethylsilane (TMS, δ = 0.00 ppm) and referenced to residual solvent peaks. All NMR experiments were conducted at room temperature unless otherwise stated. C NMR spectra.
Reversed phase analytical HPLC
Analytical samples were analysed on an Agilent 1260 Infinity Series RP HPLC with a multiple wavelength UV detector and a C18 column (Phenomenex, Kinetex EVO, 150 mm x 4.6 mm, 100 Å, 5 µm).
High resolution mass spectra were recorded on an Agilent LC-MS TOF spectrometer using
Electrospray Ionisation (ESI). m/z values are reported in Daltons.
Purification of peptides by reversed phase preparative HPLC
Peptides, on a scale of 1.00-20.0 mg, were purified on an Agilent 1260 Infinity Series RP HPLC equipped with a C18 column (Phenomenex, Kinetex EVO, 150 mm x 21.2 mm, 100 Å, 5 µm).
Solid Phase Peptide Synthesis via Automated Synthesiser
The peptides were prepared by SPPS on the Advanced ChemTech 348-Ω peptide synthesizer (Aapptec, Louisville, USA) using the standard Fmoc/t-Bu protecting group strategy and Rink Amide MBHA Resin or a Wang or 2-Chlorotrityl Resin, according to the required C-terminal functionality.
-Octreotide and Somatostatin were synthesised according to the procedure of Riera et al.
1
-Vasopressin was synthesised according to the procedure of Meienhofer et al.
2
-Oxytocin was synthesised according to the procedure of Barany et al.
3
-Bactenecin was synthesised according to the procedure of Hancock et al.
4
-α-Conotoxin MII was synthesised according to the procedure of McIntosh et al.
5
Peptides were cleaved from their resin by treatment with a TFA/phenol/TIPS/water in a ratio of 88/5.0/5.0/2.0 (v/v) for 2-3 h at room temperature, according to Barany et al. 6 The precipitated peptides were centrifuged and later purified by RP preparative HPLC. The fractions containing the desired peptides were determined by LCMS and were collected and lyophilised to yield the pure 'free' linear peptide.
The cleaved peptides containing the free thiol groups were oxidatively cyclised according to the method of Danishefsky et al. 7 The crude product was purified by RP preparative HPLC (see section
1.5.).
The fractions containing the desired peptides were determined by LCMS and were collected and lyophilised to provide the pure cyclised parent peptide.
Synthesis and characterization of SCS peptide analogues SCS N, N'-Bis-Boc L-cystine dimethyl ester
To a round bottom flask containing a stirrer bar was added 1.00 eq. of Once adjudged complete, the reaction mixture was diluted with H 2 O (10.0 mL) and lyophilised.
Then, the crude peptide was purified by RP preparative HPLC, using a linear gradient of 5% B to 
HRMS (ESI+)
Synthesis of thioacetal modified SCS 2 -α-Conotoxin MII
Bis-Thiol, Bis-Acm-protected α-Conotoxin MII (11)
The fully protected, resin-bound linear α-Conotoxin MII (10, 100 mg of resin, ca. 29.0 µmol) was liberated from the resin and all protecting groups were removed, except the acid stable Acm, by using the resin cleavage protocol as described in section 1.7. to provide the desired crude product as a fluffy white powder (5.00 mg, 89% yield). The crude product 11 was used directly in the next step. The reaction mixture was stirred at room temperature for 30 h. Upon completion, the reaction mixture was lyophilised to obtain the crude monocyclic peptide 6 as a white sold (3.2 mg, 80% yield). The crude product was used directly in the next step. 
HRMS (ESI+)
Bis-Acm-protected SCS-α-Conotoxin MII (7)
To a round bottom flask containing a stirrer bar was added 1.00 eq. of 6 (2.50 mg, 1.35 µmol) and 
Peptide stability protocols and methods
Stability Assay under Reductive Conditions
10
Independent aqueous solutions of Oxytocin and SCS Oxytocin (1.00 µmol, 1.0 mM) in 1.0 mL were added to a 100-fold excess of reduced L-Glutathione (100 µmol, 1.0 mM) in a 100 mL of PBS (pH = 7.0). The solutions were incubated at 37ºC over a period of 120 h. Samples (1.50 mL) were taken at regular pre-determined intervals and analysed directly by RP HPLC using a linear gradient of 5%-50% B at 1.25 mL/min over 10 mins. The decrease of the integration area of the compound peak was monitored with respect to time. The reductive stability assay was repeated 3 times. Compounds are screened at 10 μM. ‡ Membrane protein may change from lot to lot, the concentration used will be adjusted if necessary.
Stability Assay in Serum
V 2 R:
This assay measures binding of Compounds are screened at 10 mM. ‡ Membrane protein may change from lot to lot, the concentration used will be adjusted if necessary.
V 1B R (V 3 R):
This (Five concentrations were performed in duplicate; data points are displayed as the mean value ± SEM for each concentration.)
